Skip to main content

Advertisement

Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway

Fig. 2

Statin-Dex treatment suppresses the development of ongoing EAMG in Lewis rats. Statin-Dex and control-Dex were transferred into EAMG rats via tail vein injection at dose of 10 μg/rat on days 5 and 16 p.i. The control rats received the same volume of PBS (n = 5 rats per group). The rats in statin-Dex group exhibited lower clinical scores when compared with rats in control-Dex group (*p < 0.05 and **p < 0.01) and control group (# p < 0.05), while the clinical symptoms between control-Dex group and control group did not differ significantly. The data are expressed as mean ± SD and representative of two independent experiments

Back to article page